| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | SB590885 | GDSC1000 | pan-cancer | AAC | 0.0065 | 0.8 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.0072 | 0.8 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.8 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | -0.007 | 0.8 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.8 |